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Purpose: Bridge anticoagulation therapy is mostly utilized in patients with mechani-
cal heart valves (MHV) receiving warfarin therapy during invasive dental procedures 
because of the risk of excessive bleeding related to highly vascular supporting dental 
structures. Bridge therapy using low molecular weight heparin may be an attractive 
option for invasive dental procedures; however, its safety and cost-effectiveness com-
pared with unfractionated heparin (UFH) is uncertain. Materials and Methods: This 
study investigated the safety and cost-effectiveness of enoxaparin in comparison to 
UFH for bridge therapy in 165 consecutive patients (57±11 years, 35% men) with 
MHV who underwent invasive dental procedures. Results: This study included 75 
patients treated with UFH-based bridge therapy (45%) and 90 patients treated with 
enoxaparin-based bridge therapy (55%). The bleeding risk of dental procedures and 
the incidence of clinical adverse outcomes were not significantly different between the 
UFH group and the enoxaparin group. However, total medical costs were significantly 
lower in the enoxaparin group than in the UFH group (p<0.001). After multivariate 
adjustment, old age (≥65 years) was significantly associated with an increased risk of 
total bleeding independent of bridging methods (odds ratio, 2.51; 95% confidence in-
terval, 1.15--5.48; p=0.022). Enoxaparin-based bridge therapy (β=-0.694, p<0.001) 
and major bleeding (β=0.296, p=0.045) were significantly associated with the medical 
costs within 30 days after dental procedures. Conclusion: Considering the benefit of 
enoxaparin in cost-effectiveness, enoxaparin may be more efficient than UFH for 
bridge therapy in patients with MHV who required invasive dental procedures.
Key Words:   Anticoagulation, bridge therapy, dental procedure, low molecular 
weight heparin, mechanical heart valve
INTRODUCTION
Patients with mechanical heart valves (MHV) are at the highest risk for thrombo-
embolism without anticoagulation; therefore, lifelong oral anticoagulation (OAC) 
treatment is mandatory for preventing thromboembolic events.1-3 However, tempo-
rary discontinuation of long-acting OAC drugs (e.g., warfarin) may be inevitable 
to allow patients with MHV to undergo an invasive dental procedure or surgery. 
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farin. Initial bridge therapy started 24 to 36 h after the last 
dose of warfarin, irrespective of the bridging method. All 
patients treated with UFH-based bridging were hospitalized 
to maintain the activated partial thromboplastin time be-
tween 1.5 to 2.5 times the control values during the intrave-
nous administration of weight-adjusted UFH. Enoxaparin-
based bridge therapy was performed on an outpatient basis. 
A therapeutic dose of enoxaparin (1 mg/kg) was subcutane-
ously administered twice daily. Warfarin was resumed 12 to 
24 h after the dental procedure, and the bridge therapy was 
continued until the international normalized ratio was in the 
therapeutic range (more than 2.0 for most cases) for at least 
2 consecutive days. Total medical costs were calculated for 
the period beginning 10 days before and lasting until 30 
days after the dental procedures. The HAS-BLED score, 
which is a useful predictor of major bleeding, was calculat-
ed for all patients before their dental procedures.10 The 
bleeding risk of dental procedures was categorized as mod-
erate or high. Dental procedures with moderate bleeding 
risk included restorations with subgingival preparations 
(n=54), standard root canal therapy (n=36), simple extrac-
tions (n=46), and regional injection of local anesthesia 
(n=80). Dental procedures with high bleeding risk included 
extensive surgery (n=2), apicoectomy (root removal) (n=1), 
alveolar surgery (bone remove) (n=5), and multiple extrac-
tions (n=51). Multiple procedures involving different bleed-
ing risks were performed simultaneously in patients receiv-
ing bridge therapy; the more invasive dental procedure was 
considered the main procedure. Dental procedures with a 
low bleeding risk (e.g., supragingival scaling, local anes-
thetic injection, and simple restorations) were excluded in 
the present study.
Post-procedural bleeding
Major bleeding was defined as overt bleeding with 2 g/dL or 
greater decrease in hemoglobin, a transfusion of 2 U or more 
packed red blood cells, bleeding that required surgical inter-
vention, or life-threatening bleeding. Minor bleeding was de-
fined as any bleeding that was self-limiting such as epistaxis, 
ecchymoses, hematoma, or an incision site bleeding that did 
not require withholding anticoagulation therapy.11
Statistical analysis
Clinical characteristics are presented, based on the bridge 
therapy method used. Values are expressed as the mean± 
standard deviation for continuous variables and as numbers 
and percentages [i.e., n (%)] for categorical variables. Con-
The recommendation for the management of OAC in mi-
nor dental procedures such as simple dental extraction has 
been proposed on the basis of clinical data; however, a con-
sensus on which patients require invasive dental procedures 
is lacking.4-6 In clinical practice, conventional care with a 
short-acting anticoagulant as “bridge therapy” is commonly 
used to decrease the risk of thromboembolism during the 
cessation of OAC therapy.7-9 Intravenous unfractionated 
heparin (UFH) is the conventional medication used for 
bridging; however, it can be expensive and time-consuming, 
because periprocedural hospitalization for administering and 
laboratory monitoring is imperative. Despite the higher drug 
price of low molecular weight heparin (LMWH) compared 
with UFH, LMWH may be an attractive option for bridge 
therapy because it is relatively short-acting, requires no co-
agulation monitoring, and can be self-administered by the 
patient without hospitalization. However, there are only lim-
ited clinical data for the safety and medical costs of LMWH 
as bridge therapy for dental procedures that are associated 
with a moderate to high bleeding risk in patients with MHV. 
The present study compared the safety and cost-effective-
ness between enoxaparin and UFH for bridge therapy in 
MHV patients receiving long-term warfarin therapy who 
were to undergo invasive dental procedures and who posed 
a moderate to high bleeding risk.
MATERIALS AND METHODS
　　　
Subjects
We analyzed clinical data from 169 consecutive patients 
with MHV receiving long-term OAC therapy with warfa-
rin. Between January 2008 and December 2011, the pa-
tients visited the Severance Dental Hospital (Seoul, Korea) 
for elective invasive dental procedures. Only patients with 
stable anticoagulation status and general status were in-
cluded. Patients (n=4) who had undergone mechanical 
valve surgery within the previous 3 months were excluded. 
We finally enrolled 165 patients in this study. The study 
protocol was approved by the local ethics committee of 
our institution. Each patient provided informed consent for 
the procedure.
Dental procedures and bridge therapy
All patients stopped taking warfarin 4 days before their 
dental procedures, and they received bridge therapy with 
UFH or enoxaparin during the temporary cessation of war-
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the 165 patients, 75 (45%) patients were treated with UFH-
based bridge therapy, and 90 (55%) patients were treated 
with enoxaparin-based bridge therapy. The mean body 
mass index (BMI) and the HAS-BLED score were signifi-
cantly higher in the enoxaparin group than in the UFH 
group (BMI: 23.5±3.4 vs. 22.1±3.3, p=0.006; HAS-BLED 
score: 1.5±1.2 vs. 1.1±1.0, p=0.018). The incidence of non-
steroidal anti-inflammatory drugs was significantly higher 
in the enoxaparin group than in the UFH group (20% vs. 
5%, p=0.006).
Dental procedures, medical costs, and adverse clinical 
outcomes
The bleeding risk of the dental procedures was not signifi-
cantly different between the UFH group and the enoxaparin 
group. The incidence of clinical adverse outcomes includ-
ing total bleeding, major bleeding, stroke, and death was 
not significantly different between the UFH group and the 
tinuous variables were compared using Student’s t-test, and 
categorical variables were compared using Fisher’s exact 
test or χ2 test. Multivariate logistic regression analysis was 
used to evaluate the clinical risk factors for total bleeding 
within 30 days after dental procedures. Multivariate linear 
regression analysis was used to evaluate the clinical factors 
for medical costs. The dependent variable of medical cost 
was transformed with the natural logarithm function. SPSS 
software version 18 (SPSS Inc., Chicago, IL, USA) was 
used for all statistical analyses. All statistical tests were 
2-tailed and p<0.05 was considered significant.
RESULTS
 
Baseline characteristics
Table 1 presents the baseline characteristics of the 165 pa-
tients (57±11 years, 35% men) with MHV in this study. Of 
Table 1. Baseline Characteristics
Characteristics
Bridge anticoagulation therapy
p value
UFH (n=75) Enoxaparin (n=90)
Age (yrs)   57±10   58±13 0.471
Male sex, n (%) 21 (28) 36 (40) 0.107
Body mass index (kg/m2) 22.1±3.3 23.5±3.4 0.006
Comorbidity, n (%)
    Hypertension 24 (32) 32 (36) 0.631
    Diabetes 11 (15) 16 (18) 0.591
    Stroke 5 (7) 8 (9) 0.598
    Previous myocardial infarction 4 (5) 3 (3) 0.526
    Atrial fibrillation 37 (49) 38 (42) 0.361
    Liver cirrhosis 1 (1) 1 (1) 0.897
    Chronic lung disease 4 (5) 5 (6) 0.950
    Chronic kidney disease 2 (3) 4 (4) 0.544
    Peripheral arterial disease 1 (1) 2 (2) 0.670
LVEF (%) 62±9   59±11 0.064
HAS-BLED score   1.1±1.0   1.5±1.2 0.018
MHV position
    Mitral valve 65 (87) 71 (79) 0.191
    Aortic valve 32 (43) 40 (44) 0.819
Valve operation
    Single-valve replacement 45 (60) 65 (72) 0.097
    Multi-valve replacement 30 (40) 25 (28) 0.097
Medication, n (%)
    NSAIDs 4 (5) 18 (20) 0.006
    Beta blockers 24 (32) 29 (32) 0.976
    ACEIs or ARBs 26 (35) 36 (40) 0.481
    Statins 10 (13) 17 (19) 0.337
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; LVEF, left ventricular ejection fraction; MHV, mechanical heart valve; 
NSAIDs, non-steroidal anti-inflammatory drugs; UFH, unfractionated heparin.
Data are expressed as mean±standard deviation or as the number and percent, i.e., n (%). 
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DISCUSSION
The present study demonstrated that in patients with MHV 
who underwent invasive dental procedures, enoxaparin-
based bridge therapy had a similar complication rate but 
was more cost-effective than UFH-based bridge therapy. 
Old age (i.e. ≥65 years) was significantly associated with 
total bleeding within 30 days after the dental procedures, 
independent of the type of bridge therapy.
With respect to dental procedures or surgeries, optimal 
management varies considerably for patients at high risk of 
thromboembolism receiving long-term OAC.4-6 Periproce-
dural anticoagulation therapy is especially important in pa-
tients with MHV receiving long-term OAC, since they have 
the highest annualized risk of thromboembolic complica-
tions in the absence of anticoagulation therapy.2 A previous 
meta-analysis study reported that maintaining a regular 
dose of warfarin may not confer an increased bleeding risk 
as opposed to interrupting or modifying the warfarin dose 
for patients who undergo minor dental procedures.12 The 
enoxaparin group. However, medical costs were signifi-
cantly higher in the UFH group than in the enoxaparin group 
$2227±$3133 vs. $699±$1503, p<0.001) (Table 2).
Clinical factors associated with total bleeding
Multivariate logistic regression analysis for clinical factors 
associated with total bleeding within 30 days after dental 
procedures revealed that enoxaparin was not significantly 
associated with total bleeding after dental procedures [odds 
ratio (OR), 0.64; 95% confidence interval (CI), 0.29--1.44; 
p=0.280]. Old age (≥65 years) was an independent clinical 
factor associated with an increased risk of total bleeding af-
ter dental procedures (OR, 2.51; 95% CI, 1.15--5.48; p= 
0.022) (Table 3).
Clinical factors associated with medical costs
Multivariate linear regression analysis revealed that bridge 
therapy with enoxaparin (β=-0.694, p<0.001) and major 
bleeding (β=0.296, p=0.045) were clinical factors signifi-
cantly associated with medical costs within 30 days after 
dental procedures (Table 4).
Table 2. Medical Costs and Adverse Clinical Outcomes within 30 Days after Dental Procedures
Characteristics
Bridge therapy
p value
UFH (n=75) Enoxaparin (n=90)
Dental procedures, n (%)
    Moderate risk of bleeding 48 (64) 66 (73) 0.196
    High risk of bleeding 27 (36) 24 (27) 0.196
Total medical costs (dollar) 2227±3133 699±1503 <0.001
Adverse clinical outcomes, n (%)
    Total bleeding 23 (31) 20 (22) 0.219
    Major bleeding 5 (7) 4 (4) 0.531
    Stroke 0 (0) 1 (1) 0.360
    Death 0 (0) 1 (1) 0.360
UFH, unfractionated heparin.
Data are expressed as mean±standard deviation or as the number and percent, i.e., n (%). 
Table 3. Independent Clinical Predictors of Total Bleeding within 30 Days after Dental Procedures: Multivariate Logistic Re-
gression Analysis
                     Total bleeding events
OR (95% CI) p value
Old age (≥65 yrs) 2.51 (1.15--5.48) 0.022
Male sex 0.89 (0.40--1.97) 0.764
Body mass index (kg/m2) 1.01 (0.90--1.14) 0.829
Bridge therapy with enoxaparin 0.64 (0.29--1.44) 0.280
Procedures with high risk of bleeding 1.33 (0.58--3.05) 0.498
Multi-valve replacement 1.97 (0.91--4.28) 0.087
LVEF <45% 0.19 (0.02--1.51) 0.115
NSAIDs 1.00 (0.32--3.14) 0.996
LVEF, left ventricular ejection fraction; NSAIDs, non-steroidal anti-inflammatory drugs; OR, odds ratio; CI, confidence interval.
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py with enoxaparin was not significantly associated with ad-
verse clinical outcomes, compared to bridge therapy with 
UFH, in patients with MHV who underwent dental proce-
dures with a moderate to high bleeding risk. Old age was sig-
nificantly associated with total bleeding within 30 days after 
dental procedures, independent of the type of bridge therapy. 
These results suggested that enoxaparin could replace con-
ventional bridging with UFH without increasing complica-
tions in patients with MHV who require invasive dental pro-
cedures. Close observation of bleeding complications may be 
needed in elderly patients during bridge therapy.
Several previous studies have evaluated the medical costs 
of LMWH therapy during invasive procedures or surgeries 
in patients receiving OAC therapy who had a high risk of 
thromboembolism; the results were inconsistent. Pettinger 
and Owens18 reported that the use of LMWH may result in 
avoidable costs during dental extractions. However, in this 
study, LMWH therapy was not performed on an outpatient 
basis, and the duration of LMWH therapy was somewhat 
long, extending from 30 days before the procedures to 5 
days thereafter. Meanwhile, Spyropoulos, et al.19 reported 
that the mean total health care costs during the perioperative 
period were significantly lower in patients bridging with 
LMWH than in patients bridging with UFH for an elective 
general surgical procedures. This cost saving was associated 
with avoiding or minimizing hospitalization and no increase 
in clinical adverse events when bridging with LMWH than 
when bridging with UFH. However, this report was differ-
ent from our study in that they included patients who un-
derwent a variety of surgical procedures and the compari-
son between LMWH and UFH was not contemporary.
The present study found that enoxaparin-based bridge 
therapy in patients with MHV was significantly associated 
with reducing total medical costs without increasing adverse 
clinical events, compared to UFH-based bridge therapy dur-
American College of Chest Physicians guidelines also rec-
ommended continuing warfarin around the time of dental 
procedures in patients receiving long-term OAC.13 Howev-
er, the safety of maintaining warfarin during invasive dental 
procedures remains unclear, especially in patients with MHV. 
Dentists furthermore have concerns about excessive bleed-
ing from highly vascular supporting dental structures and a 
residual anticoagulation effect of warfarin after invasive 
procedures or surgeries. For these reasons, bridge anticoag-
ulation therapy is commonly applied in patients with MHV 
after temporary cessation of warfarin in clinical practice. In 
the present study, we compared the safety and cost-effec-
tiveness between bridge therapy with enoxaparin or UFH in 
MHV patients at moderate to high bleeding risk who re-
quired dental procedures.
While both UFH and LMWH have been used for bridge 
therapy, UFH is costly and time-consuming, as it requires ex-
tended periprocedural hospitalization and laboratory moni-
toring. The risk of heparin-induced thrombocytopenia is also 
higher in patients treated with UFH than in patients treated 
with LMWH.14 Therefore, LMWH may be an attractive op-
tion for bridge therapy, compared to UFH. Several previous 
studies reported an increased risk of hemorrhagic complica-
tions associated with general surgical procedures in patients 
treated with LMWH.15,16 However, the clinical significance 
of hemorrhagic complications related to bridge therapy with 
LMWH remains unclear in the field of dentistry.
Bui, et al.17 recently reported that enoxaparin is safe for 
outpatient bridge therapy in patients with MHV. However, 
they did not provide clinical data related to the safety of 
enoxaparin in dentistry because dental procedures were not 
included in their study, and the study included no compari-
son group that received UFH; therefore, they could not com-
pare the efficacy and safety of LMWH and UFH as bridge 
therapies. The present study demonstrated that bridge thera-
Table 4. Clinical Factors Associated with Total Medical Costs within 30 Days after Dental Procedures: Multivariate Linear Re-
gression Analysis
Total medical costs
β SE p value
Old age (≥65 yrs) -0.015 0.072 0.831
Male sex 0.009 0.008 0.898
Bridge therapy with enoxaparin -0.694 -0.629 <0.001
LVEF <45% -0.153 -0.085 0.163
Major bleeding 0.296 0.122 0.045
Minor bleeding 0.032 0.024 0.701
LVEF, left ventricular ejection fraction.
The cost of the dental procedure cost was excluded from the total medical costs.
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